ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Immunotherapy Combination Trials Q&A
A Q&A article discussing how best to achieve success in an increasingly crowded, competitive immuno-oncology field.
ICON Introduces New Drug Safety Reporting Solution
An Outsourcing Pharma article featuring commentary from Quintin Van Wyk on ICON’s new drug safety reporting platform.
Adopting a Strategy to Identify Highest Commercial Value Products
A thought leadership article written by Vicki Anastasi and published by JMDR exploring the challenges of transitioning to the new EU MDR and IVDR.
A Primer for Manufacturers Adjusting to Value-Based Healthcare
An article on the challenges of a value-based healthcare market and the importance of demonstrating clinical efficacy and cost impact of new devices.
ICON Rolls Out Digital Platform Developed with Dimension Data
An article on ICON’s new digital platform developed with Dimension Data.
Improving Pharma R&D Efficiency
Among Applied Clinical Trials' top articles on Industry Trends 2019, this article is based on ICONs whitepaper on key challenges in modern drug development.
Parkinson’s Disease Clinical Trials
An article exploring Parkinson’s disease clinical trials, featuring commentary from Peter Schueler and Haichen Yang.
ICON Issues Financial Guidance for Full Year 2019
ICON announced its financial guidance for the year ended December 31, 2019, featuring commentary from Steve Cutler.
Centre of the pharmaverse
An all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully. Read more in PharmaTimes' Jan. 2019 article.
How to Accelerate Drug Development for Patients with Rare Diseases
ICON’s Marie McCarthy, Pavel Lebesle, and Matthew McCarty discuss how to accelerate drug development for patients with rare diseases in this Pharmafile article.